Last reviewed · How we verify
Atorvastatin (Lipilou)
Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels in the blood.
Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels in the blood. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of risk of myocardial infarction and stroke.
At a glance
| Generic name | Atorvastatin (Lipilou) |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
By blocking HMG-CoA reductase, atorvastatin decreases hepatic cholesterol production and upregulates LDL receptors on liver cells, enhancing clearance of LDL cholesterol from circulation. This leads to reduced plasma LDL-C levels and improved lipid profiles, lowering cardiovascular risk.
Approved indications
- Hypercholesterolemia and dyslipidemia
- Primary and secondary prevention of cardiovascular disease
- Reduction of risk of myocardial infarction and stroke
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes (ALT/AST)
- Headache
- Rhabdomyolysis (rare)
- Nausea
Key clinical trials
- Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg (PHASE4)
- Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin (PHASE3)
- Dyslipidemia in Cardiovascular Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atorvastatin (Lipilou) CI brief — competitive landscape report
- Atorvastatin (Lipilou) updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI